Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Both Payer, Doctor Members Want to Expand Comparator PMP Removal Rule, but Mixed on Timing: Chuikyo
To read the full story
Related Article
- Chuikyo Members Remain Divided over Timing of Comparator PMP Removal
November 25, 2019
- Chuikyo Agrees on Need to Look at More Examples to Craft Pricing Models for Cell & Gene Therapies
September 12, 2019
- Don’t Expand Comparator PMP Removal Rule, Set Deduction Limit for Method II: FPMAJ
June 17, 2019
REGULATORY
- Government’s Pharma Innovation Panel to Propose Comprehensive Upgrades in Industry Policies
May 17, 2024
- Japan to Simplify Keytruda’s Optimal Use Guidelines for 4 Indications
May 17, 2024
- IBD Drugs Entyvio, Omvoh to Be Available for Self-Injection
May 17, 2024
- First Innovation Premium in 6 Years Axed for Sargmalin, “Zero” Rule Hits Yet Again
May 16, 2024
- Chuikyo OKs Listing of 18 Meds, All Get Price Premiums; Biggest Peak Sales for Beyfortus
May 16, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…